U.S. Markets open in 1 hr 4 mins

Gritstone bio, Inc. (GRTS)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.9400-0.0100 (-0.51%)
At close: 04:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.9500
Bid1.8600 x 4000
Ask1.9400 x 3200
Day's Range1.8200 - 2.0100
52 Week Range1.7100 - 14.4200
Avg. Volume1,268,751
Market Cap131.896M
Beta (5Y Monthly)0.37
PE Ratio (TTM)N/A
EPS (TTM)-1.0740
Earnings DateMar 11, 2022 - Mar 15, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.67
  • GlobeNewswire

    Gritstone to Participate in H.C. Wainwright Global Investment Conference

    EMERYVILLE, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company that aims to develop the world’s most potent vaccines, today announced that Andrew Allen, M.D., Ph.D., Co-founder, President and Chief Executive Officer of Gritstone, will participate in a fireside chat at the H.C. Wainwright Global Investment Conference, which is being held virtually and in-person from May 23-26, 2022. The fireside chat will be available on-demand begi

  • Simply Wall St.

    Are Institutions Heavily Invested In Gritstone bio, Inc.'s (NASDAQ:GRTS) Shares?

    The big shareholder groups in Gritstone bio, Inc. ( NASDAQ:GRTS ) have power over the company. Generally speaking, as a...

  • GlobeNewswire

    CORRECTION -- Gritstone Reports First Quarter 2022 Financial Results and Provides Business Update

    -- Clinical programs continue progressing, with multiple Phase 2 data catalysts from neoantigen oncology vaccine programs and additional human data evaluating self-amplifying mRNA (samRNA) vaccines against viruses expected over the next 18 months -- -- Recent presentations reinforce expertise in vaccine design and delivery and potential of Gritstone’s platform technologies in oncology and infectious diseases -- -- Cash, cash equivalents, marketable securities and restricted cash of $186.8 millio